Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 61 AL 75

Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease

Santos RX, Correia SC, Cardoso S, Carvalho C, Santos MS, Moreira PI.

J Neurochem. 2011 Jun;117(6):927-36. doi: 10.1111/j.1471-4159.2011.07262.x. Epub 2011 May 3.

Linking lipids to Alzheimer's disease: cholesterol and beyond

Di Paolo G, Kim TW.

Nat Rev Neurosci. 2011 May;12(5):284-96. doi: 10.1038/nrn3012. Epub 2011 Mar 30.

Membrane anchored and lipid raft targeted β-secretase inhibitors for Alzheimer's disease therapy

Ben Halima S, Rajendran L.

J Alzheimers Dis. 2011;24 Suppl 2:143-52. doi: 10.3233/JAD-2011-110269.

Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study

Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, Mucke HA.

J Neural Transm (Vienna). 2011 Aug;118(8):1255-9. doi: 10.1007/s00702-011-0623-8. Epub 2011 Apr 2.

Neurovascular function in Alzheimer's disease patients and experimental models

Nicolakakis N, Hamel E.

J Cereb Blood Flow Metab. 2011 Jun;31(6):1354-70. doi: 10.1038/jcbfm.2011.43. Epub 2011 Apr 6.

Rapid eye movement sleep atonia in patients with cognitive impairment

Chen PC, Wu D, Chen CC, Chi NF, Kang JH, Hu CJ.

J Neurol Sci. 2011 Jun 15;305(1-2):34-7. doi: 10.1016/j.jns.2011.03.022. Epub 2011 Apr 5.

Rehabilitating a brain with Alzheimer's: a proposal

Aranda-Abreu GE, Hernández-Aguilar ME, Manzo Denes J, García Hernández LI, Herrera Rivero M.

Clin Interv Aging. 2011;6:53-9. doi: 10.2147/CIA.S14008. Epub 2011 Feb 22.

Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Schneider LS, Dagerman KS, Higgins JP, McShane R.

Arch Neurol. 2011 Aug;68(8):991-8. doi: 10.1001/archneurol.2011.69. Epub 2011 Apr 11.

[Therapeutic approaches targeting the presumed underlying pathogenic mechanisms in Alzheimer's disease]

Delrieu J, Piau A, Vellas B.

Rev Med Interne. 2011 Jun;32 Suppl 1:S22-5. doi: 10.1016/j.revmed.2011.03.005. Epub 2011 Apr 13.

Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease

Nie Q, Du XG, Geng MY.

Acta Pharmacol Sin. 2011 May;32(5):545-51. doi: 10.1038/aps.2011.14. Epub 2011 Apr 18.

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A.

Expert Opin Biol Ther. 2011 Jun;11(6):679-86. doi: 10.1517/14712598.2011.579099. Epub 2011 Apr 19.

Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors

Mancini F, De Simone A, Andrisano V.

Anal Bioanal Chem. 2011 Jun;400(7):1979-96. doi: 10.1007/s00216-011-4963-x. Epub 2011 Apr 20.

Solanezumab for Alzheimer's disease

Samadi H, Sultzer D.

Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi: 10.1517/14712598.2011.578573. Epub 2011 Apr 20.

Regional cerebral blood flow and aberrant motor behaviour in Alzheimer's disease

Reilly TJ, Staff RT, Ahearn TS, Bentham P, Wischik CM, Murray AD.

Behav Brain Res. 2011 Sep 23;222(2):375-9. doi: 10.1016/j.bbr.2011.04.003. Epub 2011 Apr 12.

γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes

Imbimbo BP, Giardina GA.

Curr Top Med Chem. 2011;11(12):1555-70. doi: 10.2174/156802611795860942.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias